Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/1OT stock hub

FRA/1OT has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/1OTis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

411.6M

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/1OTFRA/1OT

—

Loading chart…

In the news

Latest news · FRA/1OT

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-17.5

P25 n/aP50 n/aP75 n/a

ROIC-79.1

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/1OT market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

153

Groups with data

Currency

USD

Showing 153 of 153 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	DE
Employees	23
Employees Change	-17%
Employees Change Percent	-42.5
Enterprise value	EUR 346.2M
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 411.6M
Price	EUR 2.28
Price currency	EUR
Rev Per Employee	268,544.7x
Sic	2836
Symbol	fra/1OT
Website	https://www.ovidrx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-3.55%
EV Earnings	-23.71x
EV/Sales	56.19x
P/B ratio	3.7x
P/S ratio	66.64x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Gross Profit	EUR 6.2M
Gross Profit Growth	1,181.27%
Gross Profit Growth Q	844.74%
Gross Profit Growth3 Y	68.99%
Gross Profit Growth5 Y	-10.48%
Net Income	EUR -14.6M
Pretax Margin	-240.13%
Profit Margin	-240.13%
Profit Per Employee	EUR -634,776
ROA	-21.82
Roa5y	-7.84
ROCE	-29.75
ROE	-17.51
Roe5y	-4.74
ROIC	-79.1

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	1,089.51%
Cagr3y	-9.73%
Cagr5y	-4.3%
Revenue Growth	1,181.27x
Revenue Growth Q	844.74x
Revenue Growth3 Y	68.99x
Revenue Growth5 Y	-10.48x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.06
Assets	EUR 128.6M
Cash	EUR 59.3M
Current Assets	EUR 63.1M
Current Liabilities	EUR 7M
Debt	EUR 11.4M
Debt Equity	EUR 0.1
Equity	EUR 111.3M
Liabilities	EUR 17.3M
Long Term Assets	EUR 65.5M
Long Term Liabilities	EUR 10.2M
Net Cash	EUR 65.6M
Net Cash By Market Cap	EUR 15.94
Net Cash Growth	101.01%
Net Debt Equity	EUR -0.59
Tangible Book Value	EUR 111.3M
Tangible Book Value Per Share	EUR 0.85

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	8.97
Net Working Capital	EUR -1.8M
Quick ratio	8.4
Working Capital	EUR 56.3M
Working Capital Turnover	EUR 0.11

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-3.99%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	1,087.5%
200-day SMA	1.35
3Y total return	-26.45%
50-day SMA	2
50-day SMA vs 200-day SMA	50over200
5Y total return	-19.72%
All Time High	13.25
All Time High Change	-82.79%
All Time High Date	2017-05-19
All Time Low	0.18
All Time Low Change	1,195.45%
All Time Low Date	2025-06-02
ATR	0.08
Ch YTD	67.65
High	2.28
High52	2.52
High52 Date	2026-05-04
High52ch	-9.52%
Low	2.28
Low52	0.18
Low52 Date	2025-06-02
Low52ch	1,195.46%
Ma50ch	14%
Price vs 200-day SMA	69.14%
RSI	52.37
RSI Monthly	62.43
RSI Weekly	70.22
Sharpe ratio	2.44x
Sortino ratio	4.51
Total Return	-3.99%
Tr YTD	67.65
Tr1m	16.92%
Tr1w	-9.52%
Tr3m	91.6%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR -36.1M
Operating margin	-585.2

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	149,531,355%
Shares Insiders	2.32%
Shares Institutions	29.65%
Shares Qo Q	14.85%
Shares Yo Y	3.99%
Short Ratio	2.29

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	35x
Bv Per Share	0.85
Ch1m	16.92
Ch1w	-9.52
Ch1y	1,087.5
Ch3m	91.6
Ch3y	-26.45
Ch5y	-19.72
Ch6m	105.4
Change	-1.72%
Change From Open	0
Close	2.32
Days Gap	-1.72
Depreciation Amortization	231,493.6
Earnings Date	2026-05-13
EBIT	EUR -36.1M
EBITDA	EUR -35.9M
EPS	EUR -0.2
F Score	2
Financing CF	64,053,802
Fiscal Year End	December
Founded	2,014
Investing CF	-42,460,652
Is Primary Listing	0
Last Report Date	2025-12-31
Ma150	1.53
Ma150ch	49.31%
Ma20	2.35
Ma20ch	-2.85%
Net CF	-11,198,152
Next Earnings Date	2026-05-13
Open	2.28
Ppne	10,058,525.2
Price Date	2026-05-08
Ptbv Ratio	3.7
Relative Volume	20x
Revenue	6,176,528x
SBC By Revenue	66.29x
Share Based Comp	4,094,122
Tr6m	105.41%
Volume	0
Z Score	-1.44

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/1OT pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/1OT stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/1OT?

Insider, institutional, and short-interest positioning.

Institutional ownership

+29.6%

Share of float held by funds and institutions

Insider ownership

+2.3%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

FRA/1OT momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

52.4

Neutral momentum band

Price vs 200-day MA

+69.1%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

2.44

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/1OT

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/1OT stock rating?

fra/1OT is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/1OT analysis?

The full report lives at /stocks/fra/1OT/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/1OT?

The latest report frames fra/1OT around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/1OT page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.